Durgun C
Cureus. 2023; 15(5):e39130.
PMID: 37378189
PMC: 10292013.
DOI: 10.7759/cureus.39130.
Nagose V, Kamal M, Kathuria S, Laddhad S
J Cytol. 2022; 39(3):121-125.
PMID: 36277801
PMC: 9585817.
DOI: 10.4103/joc.joc_50_22.
Schumm M, Nguyen D, Kim J, Tseng C, Chow A, Shen N
Ann Surg Oncol. 2021; 28(13):8872-8881.
PMID: 34292427
PMC: 8591007.
DOI: 10.1245/s10434-021-10375-6.
Anand B, Ramdas A, Ambroise M, Kumar N
J Thyroid Res. 2020; 2020:8095378.
PMID: 32351679
PMC: 7182964.
DOI: 10.1155/2020/8095378.
Chirayath S, Pavithran P, Abraham N, Nair V, Bhavani N, Kumar H
Indian J Endocrinol Metab. 2019; 23(3):278-281.
PMID: 31641627
PMC: 6683685.
DOI: 10.4103/ijem.IJEM_635_18.
Assessment of The Bethesda System for Reporting Thyroid Cytopathology.
Sauter J, Lehrke H, Zhang X, Al Badri O, Rodriguez-Gutierrez R, Delivanis D
Am J Clin Pathol. 2019; 152(4):502-511.
PMID: 31305880
PMC: 8204148.
DOI: 10.1093/ajcp/aqz076.
Malignancy rates for Bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB).
Mosca L, Ferraz da Silva L, Carneiro P, Chacon D, Araujo-Neto V, Araujo-Filho V
Clinics (Sao Paulo). 2018; 73:e370.
PMID: 29846414
PMC: 5960075.
DOI: 10.6061/clinics/2018/e370.
Malignancy rate in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance - An institutional experience.
Chandra S, Chandra H, Bisht S
J Cytol. 2017; 34(3):144-148.
PMID: 28701827
PMC: 5492751.
DOI: 10.4103/JOC.JOC_234_16.
Stromal tissue as an adjunct tool in the diagnosis of follicular thyroid lesions by fine-needle aspiration biopsy.
Mai K, Hogan K
Cytojournal. 2016; 13:20.
PMID: 27651822
PMC: 5019017.
DOI: 10.4103/1742-6413.189639.
Clinicopathological factors increased the risk of malignancy in thyroid nodules with atypical or follicular lesions of undetermined significance (AUS/FLUS) risk factor of malignancy in thyroid nodule with AUS/FLUS.
Hong I, Kim J, Cho Y, Park S, Kim S
Ann Surg Treat Res. 2016; 90(4):201-6.
PMID: 27073790
PMC: 4826982.
DOI: 10.4174/astr.2016.90.4.201.
A study of malignancy rates in different diagnostic categories of the Bethesda system for reporting thyroid cytopathology: An institutional experience.
Arul P, Akshatha C, Masilamani S
Biomed J. 2016; 38(6):517-22.
PMID: 27013451
PMC: 6138258.
DOI: 10.1016/j.bj.2015.08.001.
Outcome of Subclassification of Indeterminate (Thy-3) Thyroid Cytology into Thy-3a and Thy-3f.
Brophy C, Mehanna R, McCarthy J, Tuthill A, Murphy M, Sheahan P
Eur Thyroid J. 2016; 4(4):246-51.
PMID: 26835428
PMC: 4716411.
DOI: 10.1159/000441221.
Triage of patients with AUS/FLUS on thyroid cytopathology: effectiveness of the multimodal diagnostic techniques.
Kim T, Jeong D, Hahn S, Shin J, Oh Y, Ki C
Cancer Med. 2016; 5(5):769-77.
PMID: 26775803
PMC: 4864806.
DOI: 10.1002/cam4.636.
Diagnostic Thyroidectomy May Be Preferable in Patients With Suspicious Ultrasonography Features After Cytopathology Diagnosis of AUS/FLUS in the Bethesda System.
Lee Y, Kim H, Chang H, Kim S, Kim B, Chang H
Medicine (Baltimore). 2015; 94(51):e2183.
PMID: 26705204
PMC: 4697970.
DOI: 10.1097/MD.0000000000002183.
Value of TIRADS, BSRTC and FNA-BRAF V600E mutation analysis in differentiating high-risk thyroid nodules.
Zhang Y, Xu T, Cui D, Li X, Yao Q, Gong H
Sci Rep. 2015; 5:16927.
PMID: 26597052
PMC: 4657033.
DOI: 10.1038/srep16927.
Usefulness of NRAS codon 61 mutation analysis and core needle biopsy for the diagnosis of thyroid nodules previously diagnosed as atypia of undetermined significance.
Jang E, Kim W, Kim E, Kwon H, Choi Y, Jeon M
Endocrine. 2015; 52(2):305-12.
PMID: 26547216
DOI: 10.1007/s12020-015-0773-9.
Repeat Diagnoses of Bethesda Category III Thyroid Nodules: What To Do Next?.
Yoo M, Gweon H, Park A, Cho K, Kim J, Youk J
PLoS One. 2015; 10(6):e0130138.
PMID: 26115096
PMC: 4482684.
DOI: 10.1371/journal.pone.0130138.
The Implementation of the Bethesda System for Reporting Thyroid Cytopathology Improves Malignancy Detection Despite Lower Rate of Thyroidectomy in Indeterminate Nodules.
Hirsch D, Robenshtok E, Bachar G, Braslavsky D, Benbassat C
World J Surg. 2015; 39(8):1959-65.
PMID: 25809059
DOI: 10.1007/s00268-015-3032-6.
Thyroid cytopathology reporting by the bethesda system: a two-year prospective study in an academic institution.
Mehra P, Verma A
Patholog Res Int. 2015; 2015:240505.
PMID: 25688327
PMC: 4320899.
DOI: 10.1155/2015/240505.
Incidence and malignancy rates of diagnoses in the bethesda system for reporting thyroid aspiration cytology: an institutional experience.
Park J, Yoon S, Son E, Kim H, Nahm J, Hong S
Korean J Pathol. 2014; 48(2):133-9.
PMID: 24868226
PMC: 4026804.
DOI: 10.4132/KoreanJPathol.2014.48.2.133.